Drug intelligence / Profile preview

Nabelschnurblut Vita 34

Development stage: Unknown
Lead developer: Vita34
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Nabelschnurblut Vita 34 is an autologous umbilical cord blood preparation developed by Vita 34 AG. It consists of the patient's own cord blood, containing hematopoietic stem cells and immune cells. The therapy is classified as an advanced therapy medicinal product (ATMP) and has been investigated in Phase 2 clinical trials for the treatment of newly diagnosed type 1 diabetes mellitus. The mechanism involves the transfusion of autologous cells to modulate the autoimmune response against pancreatic beta-cells, aiming to preserve endogenous insulin production and improve glycemic control.

Brand names: Nabelschnurblut Vita 34
Other names: autologes Nabelschnurblut Vita34autologous umbilical cord blood Vita 34

Beyond the preview

Go deeper on Nabelschnurblut Vita 34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nabelschnurblut Vita 34.

Explore the full profile